carmustine has been researched along with Benign Supratentorial Neoplasms in 28 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "From February 2006 to January 2008, 32 patients were treated at our institution for cerebral supratentorial high grade glioma with surgery and intraoperative placement of carmustine wafers." | 9.15 | Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis. ( Brogna, C; D'elia, A; Delfini, R; Frati, A; Salvati, M; Santoro, A, 2011) |
| "This phase III Eastern Cooperative Oncology Group-Southwest Oncology Group intergroup study was conducted to determine whether three 72-hour infusions of carmustine (BiCNU) and cisplatin administered monthly before external-beam radiotherapy would improve the survival of patients with newly diagnosed glioblastoma multiforme." | 9.10 | Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncol ( Gilbert, M; Grossman, SA; Grunnet, M; Hellman, R; Mehta, M; Newton, HB; O'Neill, A; Pearlman, JL; Wagner, H, 2003) |
| "From May 1990 to November 1994, 70 consecutive patients suffering from glioblastoma multiforme were treated following surgery with conventional radiotherapy and adjuvant IV BCNU administered alone or in combination with tamoxifen." | 9.09 | Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study. ( Ameri, A; Broët, P; Cornu, P; Delattre, JY; Keime-Guibert, F; Lafitte, C; Monjour, A; Napolitano, M, 1999) |
| "To evaluate the activity and toxicity of carmustine (BCNU) and cisplatin administered as a 72-hour continuous intravenous infusion before radiation in adults with newly diagnosed high-grade astrocytomas." | 9.08 | Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. ( Grossman, SA; Kleinberg, L; Piantadosi, S; Sheidler, V; Wharam, M; Yue, N; Zeltzman, M, 1997) |
| "This Phase III trial tested the efficacy and safety of intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for the treatment of newly resected malignant glioma, comparing intra-arterial BCNU and intravenous BCNU (200 mg/sq m every 8 weeks), each regimen without or with intravenous 5-fluorouracil (1 gm/sq m three times daily given 2 weeks after BCNU)." | 9.07 | A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. ( Burger, PC; Green, SB; Mahaley, MS; Mealey, J; Ransohff, J; Robertson, JT; Selker, RG; Shapiro, WR; VanGilder, JC, 1992) |
| "In Brain Tumor Cooperative Group Study 77-02, eleven institutions randomized 603 adult patients with supratentorial malignant glioma to one of four treatment groups following surgery: conventional radiotherapy (6000 cGy in 30-35 fractions) + BCNU, conventional radiotherapy + streptozotocin, hyperfractionated (twice daily) radiotherapy (6600 cGy in 60 fractions) + BCNU, and conventional radiotherapy with misonidazole followed by BCNU." | 9.06 | Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. ( Burger, PC; Deutsch, M; Green, SB; Mealey, J; Paoletti, P; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Strike, TA, 1989) |
| "For newly diagnosed glioblastomas treated with resection in association with the standard combined chemoradiotherapy, the impact of Carmustine wafer implantation remains debated regarding postoperative infections, quality of life, and feasibility of adjuvant oncological treatments." | 7.85 | Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice. ( Abi Lahoud, G; Bou Nassif, R; Chretien, F; Devaux, B; Dezamis, E; Dhermain, F; Dumont, S; Lechapt-Zalcmann, E; Louvel, G; Oppenheim, C; Pallud, J; Parraga, E; Peeters, S; Roux, A; Sauvageon, X; Zanello, M, 2017) |
| "The study investigated if intraoperative use of carmustine wafers, particularly in combination with Stupp regimen, is a viable and safe first-line treatment option of glioblastomas." | 7.81 | Combining intraoperative carmustine wafers and Stupp regimen in multimodal first-line treatment of primary glioblastomas. ( Abi-Lahoud, G; Chrétien, F; Devaux, B; Dezamis, E; Dhermain, F; Domont, J; Louvel, G; Meder, JF; Nataf, F; Page, P; Pallud, J; Parraga, E; Pavlov, V; Robin, A; Souillard-Scemama, R; Turak, B; Varlet, P, 2015) |
| "Study the feasibility and effectiveness of a treatment associated surgery, intraoperative chemotherapy (carmustine wafers), and concomitant radiochemotherapy (temozolomide) for the management of newly diagnosed, high-grade gliomas." | 7.79 | Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. ( Colin, P; Debreuve, A; Duntze, J; Eap, C; Emery, E; Guillamo, JS; Jovenin, N; Lechapt-Zalcman, E; Litré, CF; Menei, P; Metellus, P; Peruzzi, P; Rousseaux, P; Théret, E, 2013) |
| "Conventional treatment of glioblastoma multiforme (GBM) cures less than 5% of patients." | 6.71 | Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. ( Brachman, D; Buckner, J; Curran, WJ; Lustig, R; Mehta, MP; Okunieff, P; Podgorsak, EB; Sause, W; Schultz, CJ; Seiferheld, W; Souhami, L; Werner-Wasik, M; Zamorano, L, 2004) |
| "From February 2006 to January 2008, 32 patients were treated at our institution for cerebral supratentorial high grade glioma with surgery and intraoperative placement of carmustine wafers." | 5.15 | Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis. ( Brogna, C; D'elia, A; Delfini, R; Frati, A; Salvati, M; Santoro, A, 2011) |
| "This phase III Eastern Cooperative Oncology Group-Southwest Oncology Group intergroup study was conducted to determine whether three 72-hour infusions of carmustine (BiCNU) and cisplatin administered monthly before external-beam radiotherapy would improve the survival of patients with newly diagnosed glioblastoma multiforme." | 5.10 | Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncol ( Gilbert, M; Grossman, SA; Grunnet, M; Hellman, R; Mehta, M; Newton, HB; O'Neill, A; Pearlman, JL; Wagner, H, 2003) |
| "From May 1990 to November 1994, 70 consecutive patients suffering from glioblastoma multiforme were treated following surgery with conventional radiotherapy and adjuvant IV BCNU administered alone or in combination with tamoxifen." | 5.09 | Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study. ( Ameri, A; Broët, P; Cornu, P; Delattre, JY; Keime-Guibert, F; Lafitte, C; Monjour, A; Napolitano, M, 1999) |
| "To evaluate the activity and toxicity of carmustine (BCNU) and cisplatin administered as a 72-hour continuous intravenous infusion before radiation in adults with newly diagnosed high-grade astrocytomas." | 5.08 | Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. ( Grossman, SA; Kleinberg, L; Piantadosi, S; Sheidler, V; Wharam, M; Yue, N; Zeltzman, M, 1997) |
| "Seventy-five patients harboring astrocytomas received 4 cycles of infra-ophthalmic carotid injections of BCNU, combined with vincristine intravenously and procarbazine orally." | 5.07 | Combined intra-arterial chemotherapy followed by radiation in astrocytomas. ( Hager, B; Hannisdal, E; Heier, M; Hirschberg, H; Nome, O; Watne, K; Wester, K, 1992) |
| "This Phase III trial tested the efficacy and safety of intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for the treatment of newly resected malignant glioma, comparing intra-arterial BCNU and intravenous BCNU (200 mg/sq m every 8 weeks), each regimen without or with intravenous 5-fluorouracil (1 gm/sq m three times daily given 2 weeks after BCNU)." | 5.07 | A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. ( Burger, PC; Green, SB; Mahaley, MS; Mealey, J; Ransohff, J; Robertson, JT; Selker, RG; Shapiro, WR; VanGilder, JC, 1992) |
| "In Brain Tumor Cooperative Group Study 77-02, eleven institutions randomized 603 adult patients with supratentorial malignant glioma to one of four treatment groups following surgery: conventional radiotherapy (6000 cGy in 30-35 fractions) + BCNU, conventional radiotherapy + streptozotocin, hyperfractionated (twice daily) radiotherapy (6600 cGy in 60 fractions) + BCNU, and conventional radiotherapy with misonidazole followed by BCNU." | 5.06 | Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. ( Burger, PC; Deutsch, M; Green, SB; Mealey, J; Paoletti, P; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Strike, TA, 1989) |
| "The median survival time of adults with supratentorial malignant glioma treated in clinical studies with surgery, 6 weeks of external-beam radiotherapy, and carmustine (BiCNU) is approximately 1 year." | 4.79 | Malignant gliomas in older adults with poor prognostic signs. Getting nowhere, and taking a long time to do it. ( Halperin, EC, 1995) |
| "A total of 210 patients with supratentorial/nonmetastatic glioblastoma were treated with radiation therapy (RT) plus temozolomide from 2007 to 2016 and had laboratory data on total lymphocyte counts." | 3.88 | Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma. ( Campian, JL; Chang, X; Fergus, S; Hallahan, D; Huang, J; Hui, C; Lin, AJ; Mullen, D; Rao, YJ; Rudra, S; Samson, P; Thotala, D; Tsien, C; Yang, D, 2018) |
| "For newly diagnosed glioblastomas treated with resection in association with the standard combined chemoradiotherapy, the impact of Carmustine wafer implantation remains debated regarding postoperative infections, quality of life, and feasibility of adjuvant oncological treatments." | 3.85 | Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice. ( Abi Lahoud, G; Bou Nassif, R; Chretien, F; Devaux, B; Dezamis, E; Dhermain, F; Dumont, S; Lechapt-Zalcmann, E; Louvel, G; Oppenheim, C; Pallud, J; Parraga, E; Peeters, S; Roux, A; Sauvageon, X; Zanello, M, 2017) |
| "The study investigated if intraoperative use of carmustine wafers, particularly in combination with Stupp regimen, is a viable and safe first-line treatment option of glioblastomas." | 3.81 | Combining intraoperative carmustine wafers and Stupp regimen in multimodal first-line treatment of primary glioblastomas. ( Abi-Lahoud, G; Chrétien, F; Devaux, B; Dezamis, E; Dhermain, F; Domont, J; Louvel, G; Meder, JF; Nataf, F; Page, P; Pallud, J; Parraga, E; Pavlov, V; Robin, A; Souillard-Scemama, R; Turak, B; Varlet, P, 2015) |
| "Study the feasibility and effectiveness of a treatment associated surgery, intraoperative chemotherapy (carmustine wafers), and concomitant radiochemotherapy (temozolomide) for the management of newly diagnosed, high-grade gliomas." | 3.79 | Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. ( Colin, P; Debreuve, A; Duntze, J; Eap, C; Emery, E; Guillamo, JS; Jovenin, N; Lechapt-Zalcman, E; Litré, CF; Menei, P; Metellus, P; Peruzzi, P; Rousseaux, P; Théret, E, 2013) |
| "Carmustine 80 mg/m(2) was given during RT, then every 8 weeks for 6 cycles." | 2.74 | Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. ( Curran, WJ; Diaz, A; Gilbert, MR; Kresel, JJ; Mehta, MP; Michalski, JM; Moughan, J; Purdy, J; Simpson, J; Tsien, C, 2009) |
| "Conventional treatment of glioblastoma multiforme (GBM) cures less than 5% of patients." | 2.71 | Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. ( Brachman, D; Buckner, J; Curran, WJ; Lustig, R; Mehta, MP; Okunieff, P; Podgorsak, EB; Sause, W; Schultz, CJ; Seiferheld, W; Souhami, L; Werner-Wasik, M; Zamorano, L, 2004) |
| " The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days." | 2.70 | Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. ( Affronti, ML; Cokgor, L; Early, M; Edwards, S; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S, 2001) |
| "Patients with anaplastic astrocytoma, or glioblastoma multiforme, age 18-70 years with a Karnofsky performance status of 40-100 were stratified according to age, Karnofsky performance status, and histology, and were randomized." | 2.67 | Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. ( Ahmad, K; Constine, LS; Curran, WJ; Mohiuddin, M; Murray, K; Nelson, DF; Nelson, JS; Powlis, WD; Scott, C; Weinstein, AS, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 8 (28.57) | 18.2507 |
| 2000's | 12 (42.86) | 29.6817 |
| 2010's | 6 (21.43) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Roux, A | 2 |
| Aboubakr, O | 1 |
| Elia, A | 1 |
| Moiraghi, A | 1 |
| Benevello, C | 1 |
| Fathallah, H | 1 |
| Parraga, E | 3 |
| Oppenheim, C | 2 |
| Chretien, F | 3 |
| Dezamis, E | 3 |
| Zanello, M | 2 |
| Pallud, J | 3 |
| Beez, T | 1 |
| Burgula, S | 1 |
| Kamp, M | 1 |
| Rapp, M | 1 |
| Steiger, HJ | 1 |
| Sabel, M | 1 |
| Peeters, S | 1 |
| Bou Nassif, R | 1 |
| Abi Lahoud, G | 1 |
| Lechapt-Zalcmann, E | 1 |
| Dhermain, F | 2 |
| Dumont, S | 1 |
| Louvel, G | 2 |
| Sauvageon, X | 1 |
| Devaux, B | 2 |
| Rudra, S | 1 |
| Hui, C | 1 |
| Rao, YJ | 1 |
| Samson, P | 1 |
| Lin, AJ | 1 |
| Chang, X | 1 |
| Tsien, C | 2 |
| Fergus, S | 1 |
| Mullen, D | 1 |
| Yang, D | 1 |
| Thotala, D | 1 |
| Hallahan, D | 1 |
| Campian, JL | 1 |
| Huang, J | 1 |
| Pavlov, V | 1 |
| Page, P | 1 |
| Abi-Lahoud, G | 1 |
| Nataf, F | 1 |
| Robin, A | 1 |
| Varlet, P | 1 |
| Turak, B | 1 |
| Domont, J | 1 |
| Souillard-Scemama, R | 1 |
| Meder, JF | 1 |
| Licci, S | 1 |
| Narciso, P | 1 |
| Moughan, J | 1 |
| Michalski, JM | 1 |
| Gilbert, MR | 1 |
| Purdy, J | 1 |
| Simpson, J | 1 |
| Kresel, JJ | 1 |
| Curran, WJ | 4 |
| Diaz, A | 1 |
| Mehta, MP | 2 |
| Salvati, M | 1 |
| D'elia, A | 1 |
| Frati, A | 1 |
| Brogna, C | 1 |
| Santoro, A | 1 |
| Delfini, R | 1 |
| Duntze, J | 1 |
| Litré, CF | 1 |
| Eap, C | 1 |
| Théret, E | 1 |
| Debreuve, A | 1 |
| Jovenin, N | 1 |
| Lechapt-Zalcman, E | 1 |
| Metellus, P | 1 |
| Colin, P | 2 |
| Guillamo, JS | 1 |
| Emery, E | 1 |
| Menei, P | 1 |
| Rousseaux, P | 1 |
| Peruzzi, P | 1 |
| Afra, D | 1 |
| Sipos, L | 1 |
| Vitanovics, D | 1 |
| Durando, X | 2 |
| Lemaire, JJ | 1 |
| Tortochaux, J | 1 |
| Van-Praagh, I | 1 |
| Kwiatkowski, F | 2 |
| Vincent, C | 1 |
| Bailly, C | 1 |
| Verrelle, P | 2 |
| Irthum, B | 1 |
| Chazal, J | 1 |
| Bay, JO | 2 |
| Grossman, SA | 2 |
| O'Neill, A | 1 |
| Grunnet, M | 1 |
| Mehta, M | 1 |
| Pearlman, JL | 1 |
| Wagner, H | 1 |
| Gilbert, M | 1 |
| Newton, HB | 1 |
| Hellman, R | 1 |
| Souhami, L | 1 |
| Seiferheld, W | 1 |
| Brachman, D | 1 |
| Podgorsak, EB | 1 |
| Werner-Wasik, M | 2 |
| Lustig, R | 1 |
| Schultz, CJ | 1 |
| Sause, W | 1 |
| Okunieff, P | 1 |
| Buckner, J | 1 |
| Zamorano, L | 1 |
| Vordermark, D | 1 |
| Kölbl, O | 1 |
| Kondziolka, D | 1 |
| Lunsford, LD | 1 |
| Flickinger, JC | 1 |
| Ducray, F | 1 |
| Cartalat-Carel, S | 1 |
| Pelissou-Guyotat, I | 1 |
| Mahla, K | 1 |
| Audra, P | 1 |
| Gaucherand, P | 1 |
| Honnorat, J | 1 |
| Trouillas, P | 1 |
| Jacques-Olivier, B | 1 |
| Linassier, C | 2 |
| Claude, L | 1 |
| Biron, P | 2 |
| Pierre, B | 1 |
| Xavier, D | 1 |
| Pierre, V | 1 |
| Fabrice, K | 1 |
| Rosti, G | 1 |
| Giovanni, R | 1 |
| Demirer, T | 1 |
| Taner, D | 1 |
| Halperin, EC | 1 |
| Nelson, DF | 2 |
| Scott, C | 1 |
| Nelson, JS | 2 |
| Weinstein, AS | 2 |
| Ahmad, K | 1 |
| Constine, LS | 1 |
| Murray, K | 1 |
| Powlis, WD | 1 |
| Mohiuddin, M | 1 |
| Scott, CB | 1 |
| Gaspar, LE | 1 |
| Murray, KJ | 1 |
| Fischbach, JA | 1 |
| Benboubker, L | 1 |
| Velut, S | 1 |
| Calais, G | 1 |
| Saudeau, D | 1 |
| Jan, M | 1 |
| Autret, A | 1 |
| Berger, C | 1 |
| Colombat, P | 1 |
| Wharam, M | 1 |
| Sheidler, V | 1 |
| Kleinberg, L | 1 |
| Zeltzman, M | 1 |
| Yue, N | 1 |
| Piantadosi, S | 1 |
| Napolitano, M | 1 |
| Keime-Guibert, F | 1 |
| Monjour, A | 1 |
| Lafitte, C | 1 |
| Ameri, A | 1 |
| Cornu, P | 1 |
| Broët, P | 1 |
| Delattre, JY | 1 |
| Vlassenko, AG | 1 |
| Thiessen, B | 1 |
| Beattie, BJ | 1 |
| Malkin, MG | 1 |
| Blasberg, RG | 1 |
| Gururangan, S | 1 |
| Cokgor, L | 1 |
| Rich, JN | 1 |
| Edwards, S | 1 |
| Affronti, ML | 1 |
| Quinn, JA | 1 |
| Herndon, JE | 1 |
| Provenzale, JM | 1 |
| McLendon, RE | 1 |
| Tourt-Uhlig, S | 1 |
| Sampson, JH | 1 |
| Stafford-Fox, V | 1 |
| Zaknoen, S | 1 |
| Early, M | 1 |
| Friedman, AH | 1 |
| Friedman, HS | 1 |
| Watne, K | 1 |
| Hannisdal, E | 1 |
| Nome, O | 1 |
| Hager, B | 1 |
| Wester, K | 1 |
| Heier, M | 1 |
| Hirschberg, H | 1 |
| Shapiro, WR | 2 |
| Green, SB | 2 |
| Burger, PC | 2 |
| Selker, RG | 2 |
| VanGilder, JC | 1 |
| Robertson, JT | 2 |
| Mealey, J | 2 |
| Ransohff, J | 1 |
| Mahaley, MS | 1 |
| Deutsch, M | 1 |
| Strike, TA | 1 |
| Ransohoff, J | 1 |
| Paoletti, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme[NCT00003417] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 1998-09-30 | Completed | ||
| A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME[NCT00002545] | Phase 3 | 200 participants (Anticipated) | Interventional | 1994-02-28 | Completed | ||
| A Family Study of Adults With Glioma[NCT00339352] | 1,871 participants (Actual) | Observational | 1999-03-11 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for carmustine and Benign Supratentorial Neoplasms
| Article | Year |
|---|---|
Malignant gliomas in older adults with poor prognostic signs. Getting nowhere, and taking a long time to do it.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine | 1995 |
14 trials available for carmustine and Benign Supratentorial Neoplasms
| Article | Year |
|---|---|
Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Carmustine; Combined Modality Therapy; Drug A | 2009 |
Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Carmustine; Combined Modali | 2011 |
[Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astr | 2002 |
Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncol
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2003 |
Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; F | 2004 |
Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
Topics: Adult; Aged; Astrocytoma; Carmustine; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; | 1993 |
Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; F | 1996 |
High-dose BCNU with ABMT followed by radiation therapy in the treatment of supratentorial glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Carmustine; Combined Mo | 1996 |
Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astr | 1997 |
Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Carmustine; Combine | 1999 |
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Cohort Studies | 2001 |
Combined intra-arterial chemotherapy followed by radiation in astrocytomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astro | 1992 |
A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 1992 |
Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Carmustine; Combined Modality Therapy; Glioblastoma; Glioma; H | 1989 |
13 other studies available for carmustine and Benign Supratentorial Neoplasms
| Article | Year |
|---|---|
Carmustine wafer implantation for supratentorial glioblastomas, IDH-wildtype in "extreme" neurosurgical conditions.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cohort Studies; C | 2023 |
Space-Occupying Tumor Bed Cysts as a Complication of Modern Treatment for High-Grade Glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Edema; Carmustine; Central Nervous System Cysts; C | 2017 |
Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality The | 2017 |
Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bevacizumab; Carmu | 2018 |
Combining intraoperative carmustine wafers and Stupp regimen in multimodal first-line treatment of primary glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Carmustine; Chemoradiother | 2015 |
Myelomatous meningitis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Fem | 2008 |
Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy, Adjuvant; Dacarbazine | 2013 |
High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Carmustine; Combined Modali | 2003 |
Lack of survival benefit after stereotactic radiosurgery boost for glioblastoma multiforme: randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients
Topics: Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; Female; Glioblastoma; Huma | 2005 |
In regard to Dr. Souhami et al. (Int J Radiat Oncol Biol Phys 2004;60:853-860).
Topics: Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; Glioblastoma; Humans; Radi | 2005 |
[Management of malignant gliomas diagnosed during pregnancy].
Topics: Abortion, Therapeutic; Adrenal Cortex Hormones; Adult; Algorithms; Anesthesia, General; Antineoplast | 2006 |
Does high-dose carmustine increase overall survival in supratentorial high-grade malignant glioma? An EBMT retrospective study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; F | 2007 |
Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biologica | 2000 |